Clinical Trial Update: Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for the irbesartan/hydrochlorothiazide fixed-dose combination in moderate hypertension; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Irbesartan/Hydrochlorothiazide (irbesartan/hydrochlorothiazide)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hypertension | Phase 3 | Status: COMPLETED